SMAIO posts investor presentation on first-half 2026 business update

• SMAIO reported H1 2026 revenue of EUR 5.13 million, up 3% year on year, driven by implant sales growth.
• U.S. implant sales rose 10% to USD 4.5 million excluding FX, or up 3% to EUR 3.9 million with a EUR 0.3 million FX headwind.
• U.S. revenue impact estimated at about USD 0.7 million from a temporary absence of a key surgeon during the last four months.
• U.S. network expanded with 13 new surgeons generating USD 0.4 million; 34 active surgeons as of June 30, 2026.
• Cash stood at EUR 7 million at June 30, 2026; March ABSA issue raised EUR 3.6 million with 515,041 ABSA priced at EUR 7.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SMAIO SA published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.